ORKA
Oruka Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$92.51
+1.67%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−37.1x
Market Cap
$6.13B
MomentumView details →
1D Return
+1.67%
YTD Return
+204.32%
RSI (14)
41.6
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−37.1x
Market Cap
$6.13B
RSI (14)
41.6
MomentumView details →
1D Return
+1.67%
YTD Return
+204.32%
SummaryUpdated Jun 1, 2026
Oruka Therapeutics, Inc. (NASDAQ:ORKA) is a clinical-stage biotechnology company founded to develop innovative monoclonal antibody treatments for inflammatory and immunological diseases. Based in Menlo Park, California, the company focuses specifically on developing therapies for psoriasis and other immune-mediated inflammatory conditions. As a pre-revenue biotech firm, Oruka is currently advancing its pipeline of experimental drugs through clinical trials, with its lead candidates being ORKA-001 and ORKA-002.
Similar companies
Latest newsMore news →
BlackRock Inc. acquired a new minority stake in Oruka Therapeutics, Inc., purchasing 4,990,181 shares valued at approximately $474,916,000, representing about 8.27% ownership, as disclosed in a 13F filing.11d agoOruka Therapeutics, Inc. appointed Todd Edwards as Chief Commercial Officer, effective with a base salary of $525,000, a target bonus of 40% of annual base salary, a signing bonus of $200,000, and equity grants including a stock option for 20,000 shares and restricted stock units for 100,000 shares of Oruka common stock.12d ago